A Halia publication has been featured in the Journey of Drug Targeting: “Ofirnoflast (HT-6184): A first-in-class, orally bioavailable NEK7 inhibitor currently undergoing Phase 2 clinical evaluation.” Ofirnoflast targets inflammation at its source by preventing NLRP3 inflammasome formation and promoting its disassembly – essentially disrupting the root cause rather than just managing symptoms.
